<html>
<head>
<title>Clinical Evidence</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="#999999">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="000868" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/ISHThiazidestitle.gif" width="580" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ISHandThiazides.html"><img src="../Assets/CE1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ISHandThiazides.html"><img src="../Assets/CE2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ISHandThiazides.html"><img src="../Assets/CE3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ISHandThiazides.html"><img src="../Assets/CE4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ISHandThiazides.html"><img src="../Assets/CE5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ISHandThiazides.html"><img src="../Assets/CE6.gif" width="121" height="37" name="VA" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/CEheader.gif" width="330" height="50" align="baseline"><img src="../Assets/CEheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><font color="#B70000"><br>
              Last Updated: Janurary, 2002</font><br>
              <table width="90%" border="0">
                <tr bordercolordark="#ffffff" bordercolorlight="#c2c2c2"> 
                  <td class=heading id=heading><TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
                      <TBODY>
                        <TR> 
                          <TD class=heading id=heading> <SCRIPT src="ISH_and_Thiazides_CE_content_files092101/ish%20and%20hctz011402_files/0205_i1_files/0205_i1.0"></SCRIPT> 
                            <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT> 
                            <TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular disorders</SECTION></SPAN><IMG height=10 
            src="ISH_and_Thiazides_CE_content_files092101/ish%20and%20hctz011402_files/0205_i1_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
                                    <SPAN class=localhead id=localhead><TOPIC>Primary 
                                    prevention</TOPIC><IMG height=10 src="ISH_and_Thiazides_CE_content_files092101/ish%20and%20hctz011402_files/0205_i1_files/spacer.gif" 
            width=10 align=absMiddle border=0></SPAN></TD>
                                </TR>
                                <TR> 
                                  <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=0205_CONTRIB&amp;t=document-frame.htm&amp;2.0&amp;p="><EM>Clinical 
                                    Evidence</EM> writers on primary prevention</A><IMG height=10 
            src="ISH_and_Thiazides_CE_content_files092101/ish%20and%20hctz011402_files/0205_i1_files/spacer.gif" width=10 align=absMiddle 
        border=0></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
                              drugs</H1>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD width="10%" vAlign=top bgcolor="#333333" class=question id=question><B><SPAN 
            class=question-title id=question-title><font color="#FFFFFF">QUESTION</font></SPAN></B></TD>
                                  <TD bgcolor="cccccc" class=question id=question>&nbsp;<B>What 
                                    are the effects of drug treatment in primary 
                                    hypertension?</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A 
      name=I1> 
                            <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Versus 
                              placebo</H2>
                            <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR class=option id=option> 
                                  <TD 
          width="10%" vAlign=top bgcolor="000099" class=option id=option style="PADDING-LEFT: 2px"><SPAN class=option-title 
            id=option-title><font color="#FFFFFF">OPTION</font>&nbsp;&nbsp;&nbsp;</SPAN></TD>
                                  <TD 
            width="100%" bgcolor="ccccff" class=option id=option style="PADDING-LEFT: 2px"><B>Antihypertensive 
                                    drugs versus placebo</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            </A> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD><A name=I1-SUMSTATEMENT><B> 
                                    <P style="MARGIN-LEFT: 3px" align=justify>Many 
                                      systematic reviews of RCTs have found that 
                                      drug treatment decreases the risk of fatal 
                                      and non-fatal stroke, cardiac events, and 
                                      total mortality in specific populations 
                                      of people. The biggest benefit is seen in 
                                      people with highest baseline risk of cardiovascular 
                                      disease.</P>
                                    </B></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> 
                                <P align=justify><FONT color=#0033cc><A 
            name=I1-BENEFITS><B>Benefits: </B></A></FONT>We found many systematic 
                                  reviews. One review (search date 1997, 17 RCTs 
                                  with morbidity and mortality outcomes, duration 
                                  &gt;&nbsp;1 year, 37&nbsp;000 people) found 
                                  that antihypertensive drugs versus placebo produced 
                                  variable reductions of systolic/diastolic blood 
                                  pressure that averaged around 12–16/5–10&nbsp;mm&nbsp;Hg. 
                                  <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
                                  It found evidence of benefit in total death 
                                  rate, cardiovascular death rate, stroke, major 
                                  coronary events, and congestive cardiac failure, 
                                  but the absolute results depended on age and 
                                  the severity of the hypertension (see below). 
                                  The biggest benefit was seen in those with the 
                                  highest baseline risk. The trials mainly compared 
                                  placebo versus diuretics (usually thiazides 
                                  with the addition of amiloride or triamterene) 
                                  and versus ß blockers (usually atenolol or metoprolol) 
                                  in a stepped care approach. <font color="#FF0000">One 
                                  systematic review (search date 1999, 8 RCTs, 
                                  15&nbsp;693 people) found that, in people over</font> 
                                  <font color="#FF0000">60 years old with systolic 
                                  hypertension, treatment of systolic pressures 
                                  greater than 160&nbsp;mm&nbsp;Hg decreased total 
                                  mortality and fatal and non-fatal cardiovascular 
                                  events. Absolute benefits were greater in men 
                                  than women, in people aged over 70, and in those 
                                  with prior cardiovascular events or wider pulse 
                                  pressure. The relative hazard rates associated 
                                  with a 10&nbsp;mm&nbsp;Hg higher initial systolic 
                                  blood pressure were 1.26 (P&nbsp;=&nbsp;0.0001) 
                                  for total mortality, 1.22 (P&nbsp;=&nbsp;0.02) 
                                  for stroke, but only 1.07 (P&nbsp;=&nbsp;0.37) 
                                  for coronary events. Active treatment reduced 
                                  total mortality (RR 0.87, 95% CI 0.78 to 0.98, 
                                  P&nbsp;=&nbsp;0.02).</font> <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF123">[123]</A> 
                                  <B>Target diastolic blood pressure:</B> We found 
                                  one RCT (18&nbsp;790 people, mean age 62 years, 
                                  diastolic blood pressures between 100–115&nbsp;mm&nbsp;Hg), 
                                  which aimed to evaluate the effects on cardiovascular 
                                  risk of target diastolic blood pressures of 
                                  90, 85, and 80&nbsp;mm&nbsp;Hg. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF124">[124]</A> 
                                  However, mean achieved diastolic blood pressures 
                                  were 85, 83, and 81&nbsp;mm&nbsp;Hg, which limited 
                                  power to detect differences among groups. There 
                                  were no significant differences in major cardiovascular 
                                  events among the three groups.</P>
                              </TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I1-HARMS><B>Harms: 
                                      </B></A></FONT><B>Mortality and major morbidity:</B> 
                                      One systematic review of RCTs comparing 
                                      diuretics and ß blockers versus placebo 
                                      found no increase in non-cardiovascular 
                                      mortality in treated people. <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
                                      One systematic review (9 case control and 
                                      3 cohort studies) found that long term diuretic 
                                      use may be associated with an increased 
                                      risk of renal cell carcinoma (OR in case 
                                      control studies 1.55, 95% CI 1.4 to 1.7). 
                                      <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF125">[125]</A> 
                                      Absolute risks cannot be calculated from 
                                      these studies, but renal cell carcinoma 
                                      is rare, so the absolute risk increase of 
                                      any real effect would be correspondingly 
                                      small. Renal cell carcinoma can cause hypertension; 
                                      this fact may have confounded the results 
                                      of these studies. <B>Quality of life and 
                                      tolerability:</B> One systematic review 
                                      and several recent trials found that quality 
                                      of life was not adversely affected and may 
                                      be improved in those who remain on treatment. 
                                      <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF126">[126]</A> 
                                      <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF127">[127]</A> 
                                    </P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I1-COMMENT><B>Comment: 
                                      </B></A></FONT>Trials included people who 
                                      were healthier than the general population, 
                                      with lower rates of cardiovascular risk 
                                      factors, cardiovascular disease, and comorbidity. 
                                      People with higher cardiovascular risk can 
                                      expect greater short term absolute risk 
                                      reduction than seen in the trials, whereas 
                                      people with major competing risks such as 
                                      terminal cancer or end stage Alzheimer's 
                                      disease can expect smaller risk reduction. 
                                      In the systematic review, <A 
            href="http://www.evidence.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i1?fn=document-frame.htm&amp;f=templates#REF122">[122]</A> 
                                      five of the trials were in middle aged adults 
                                      with mild to moderate hypertension. Seven 
                                      of the trials were in people older than 
                                      60 years. On average, every 1000 person 
                                      years of treatment in older adults prevented 
                                      five strokes (95% CI 2 to 8), three coronary 
                                      events (95% CI 1 to 4), and four cardiovascular 
                                      deaths (95% CI 1 to 8). Drug treatment in 
                                      middle aged adults prevented one stroke 
                                      (95% CI 0 to 2) for every 1000 person years 
                                      of treatment and did not significantly affect 
                                      coronary events or mortality.</P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A name=references></A> <TABLE cellSpacing=0 cellPadding=0 border=0>
                              <TBODY>
                                <TR> 
                                  <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
                                  <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD>
                                </TR>
                                <TR> 
                                  <TD class=key-message id=key-message width=90 
            bgColor=cccccc><B>References</B></TD>
                                  <TD width="100%">&nbsp;</TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellPadding=2 width="100%" align=center>
                              <TBODY>
                                <TR><A class=reference id=reference name=REF122></a> 
                                  <TD class=reference id=reference vAlign=top width=15>122. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Gueyffier 
                                    F, Froment A, Gouton M. New meta-analysis 
                                    of treatment trials of hypertension: improving 
                                    the estimate of therapeutic benefit. <EM>J 
                                    Hum Hypertens</EM> 1996;10:1–8. Search date 
                                    1997; primary source Medline. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=96219361");' style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF123></a> 
                                  <TD class=reference id=reference vAlign=top width=15>123. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Staessen 
                                    JA, Gasowski J, Wang JG, et al. Risks of untreated 
                                    and treated isolated systolic hypertension 
                                    in the elderly: meta-analysis of outcome trials. 
                                    <EM>Lancet</EM> 2000;355:865–872. Search date 
                                    1999; primary sources other systematic reviews 
                                    and reports from collaborative trialists. 
                                    <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20214375");' style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF124></a> 
                                  <TD class=reference id=reference vAlign=top width=15>124. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Hansson 
                                    L, Zanchetti AZ, Carruthers SG, et al. Effects 
                                    of intensive blood pressure lowering and low-dose 
                                    aspirin in patients with hypertension: principal 
                                    results of the hypertension optimal treatment 
                                    (HOT) trial. <EM>Lancet</EM> 1998;351:1755–1762. 
                                    <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=98297870");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF125></a> 
                                  <TD class=reference id=reference vAlign=top width=15>125. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Grossman 
                                    E, Messerli FH, Goldbourt U. Does diuretic 
                                    therapy increase the risk of renal cell carcinoma? 
                                    <EM>Am J Cardiol</EM> 1999;83:1090–1093. Search 
                                    dates 1966 to 1998; primary sources Medline. 
                                    <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=99204801");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF126></a> 
                                  <TD class=reference id=reference vAlign=top width=15>126. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Beto 
                                    JA, Bansal VK. Quality of life in treatment 
                                    of hypertension: a meta-analysis of clinical 
                                    trials. <EM>Am J Hypertens</EM> 1992;5:125–133. 
                                    Search date 1990; primary sources Medline, 
                                    ERIC. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=92247409");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF127></a> 
                                  <TD class=reference id=reference vAlign=top width=15>127. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Croog 
                                    SH, Levine S, Testa MA. The effects of antihypertensive 
                                    therapy on quality of life. <EM>N Engl J Med</EM> 
                                    1986;314:1657–1664. <A 
            href='javascript:showWindow("http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=86230742");' 
            style="FONT-SIZE: 8pt">[PubMed]</A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD vAlign=bottom width="50%"> 
                                  
                              <TD align=right width="50%"><IMG src="../Assets/ce-pagebrand.jpg" 
            alt="BMJ - Clinical Evidence" width="89" height="44" 
            border=0></TD>
                                </TR>
                                <TR> 
                                  <TD align=left width="50%"> 
                                  <TD align=right width="50%"><A 
            href="http://www.evidence.org/lpBinCE/lpext.dll?f=id&amp;id=201106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <SCRIPT language=JavaScript>
			var purl = "0205.PDF"; 
</SCRIPT> 
                            <SCRIPT language=JavaScript src="ISH_and_Thiazides_CE_content_files092101/ish%20and%20hctz011402_files/0205_i1_files/stats.js" 
      type=text/javascript></SCRIPT> <SCRIPT language=JavaScript type=text/javascript><!--
  stats("MC-MTg0OQ==-45MT-Y2Nz","","","");
//--></SCRIPT> <NOSCRIPT>
                            <IMG height=1 src="" width=1 
  border=0></NOSCRIPT></TD>
                        </TR>
                      </TBODY>
                    </TABLE> </td>
                </tr>
                <tr> 
                  <td>
                    <div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div>
                  </td>
                </tr>
              </table>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="#3333FF"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
